EVERSANA Partners with Lyfegen to Bring AI to Drug Pricing and Market Access

Stock.adobe.com

Many companies and investors believe that AI has to potential to reshape various elements of the pharma industry. Two companies, Lyfegen and EVERSANA, recently announced a partnership aimed at using AI to improve drug pricing and access.¹

Lyfegen is a global management firm focused on drug market access, pricing, and rebates, while EVERSANA is a provider of commercial services to the pharma industry. As part of the partnership, EVERSANA will combine its global pricing and market access platform NAVLIN with Lyfegen’s Publice Drug Agreement Library. The hope is that AI-powered technology will find new connections between drugs and specific markets and streamline the decision-making process for drug developers.

In a press release, EVERSANA CEO Jim Lang said, “Together with Lyfegen we can harness the power of AI to address one of the biggest challenges in healthcare—helping patients get timely access to life-saving medicines. By uniting our expertise and our global pricing innovations, we have the opportunity to deliver a solution that simplifies decision-making and improves access in healthcare systems worldwide."

Lyfegen CEO Girisha Fernando added, “Our mission at Lyfegen has always been to create a more sustainable and equitable healthcare environment. Through this partnership with EVERSANA, we are taking a giant step toward that future. By integrating EVERSANA's price and access data into our combined offerings, we're not just solving today's challenges—we're building a foundation for a smarter, more efficient drug access and pricing landscape."

This is just EVERSANA’s latest partnership. In October of last year, the company announced an agreement with Oracle Argus Cloud to launch a new AI-powered platform designed for pharmacovigilance customers.²

In a press release issued at the time, Lang said, “We believe that pharmacovigilance services across the life sciences industry are powered by innovation and transformational thinking. Together with Oracle's leading systems, we are doing just this, combining our experience and operational excellence with best-in-class systems to drive better outcomes and put patient safety first."

He continued, “Today's drug safety industry demands that service providers deliver critical medical information to doctors and patients in their region and at any time. Our investments in global experts, top talent, and transformational technology will help bring this commitment to life."

In December of last year, EVERSANA also announced a partnership with ConTIPI Medical to launch a non-surgical medical device proVate for women with pelvic organ prolapse.³

In a press release issued at the time, Lang said, “Bringing a new product to market is a complex, but critically important process. We're honored to have helped ConTIPI successfully launch through our commercialization expertise and integrated model."

"Today marks a significant milestone in women's health in the United States as we are thrilled to see that ProVate is now available for physicians to prescribe for patients with pelvic organ prolapse," added Dr. Elan Ziv, MD, OBGYN, Urogynecologist, CEO & Medical Director with ConTIPI Medical. "EVERSANA has been a tremendous partner throughout the commercialization process, and we look forward to continued work with their best-in-class team."

SOURCES

Lyfegen and EVERSANA Collaborate to Revolutionize Drug Pricing and Access with AI-Driven Insights. EVERSANA. January 28, 2025. https://www.prnewswire.com/news-releases/lyfegen-and-eversana-collaborate-to-revolutionize-drug-pricing-and-access-with-ai-driven-insights-302361053.html

EVERSANA Transforms Pharmacovigilance & Drug Safety Industry with Oracle Collaboration, New Global Patient Support Model. EVERSANA. October 10, 2024. Accessed January 29, 2025. https://www.prnewswire.com/news-releases/eversana-transforms-pharmacovigilance--drug-safety-industry-with-oracle-collaboration-new-global-patient-support-model-302272577.html

ConTIPI Medical & EVERSANA Announce U.S. Commercial Launch of Non-Surgical Medical Device ProVate for Women With Pelvic Organ Prolapse. EVERSANA. December 10, 2024. Accessed January 29, 2025. https://www.prnewswire.com/news-releases/contipi-medical--eversana-announce-us-commercial-launch-of-non-surgical-medical-device-provate-for-women-with-pelvic-organ-prolapse-302327423.html